🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Hey folks, I'll be in NYC Sunday & Monday -- would love to catch up with folks working on any subset of vaccines, ML for bio, robotics, and public policy. Feel free to comment here or email me at my_first_name [at] popvax dot com.

I recently spoke at Ethereum Devconnect ARG about PopVax 🇮🇳’s work developing novel mRNA vaccines to save 1 million lives each year, as part of a series of talks organized by vitalik.eth around his d/acc vision – defensive, differential, and decentralized accelerationism. (1/4)

Vitalik, via his biosecurity and public health organization Balvi, was the first to believe in our vision of leveraging the 10x cost & speed advantages of doing R&D in India to develop fundamentally broader, safer, and more transparent vaccines, and is our largest funder. (2/4)

Our soon-to-be open sourced COVID-19 vaccine funded by Vitalik & Balvi is designed to protect against both current & future variants of SARS-CoV-2, aligning with the goals of d/acc. It will enter a Phase I trial in the US conducted & sponsored by NIH NIAID News in 2025. (3/4)

We now seek to apply our v/acc approach – vaccine accelerationism – to HCV, Strep A, and TB, three pathogens which collectively kill ~2 million people a year, and for which there are no existing effective vaccines. More in the video below: (4/4) youtu.be/OXxo49WrODQ

While we all certainly hope that H5N1 influenza doesn’t mutate into a strain that causes a pandemic in humans, there is the distinct and unnerving possibility that it does, as Alex Tabarrok (h/t Patrick Collison) and commentary in the NEJM have recently noted.

How do you make a 250x better vaccine at 1/10 the cost? Develop it in India. (Soham Sankaran, Ep #2) There's a lot of discussion these days on how China's biotech market is on track to bypass the US's. I wondered: shouldn't we have observed the exact same phenomenon with India?

I'm delighted to announce that PopVax 🇮🇳 has been awarded $2 million by the US Biomedical Advanced Research and Development Authority (BARDA) as a winner of the first stage of BARDA’s Patch Forward Prize for our seasonal influenza vaccine, along with our partner LTS. (1/12)

We need fundamentally better flu vaccines that are robust to at least 6 months-1 year of strain mutation such that they can deliver 80%+ efficacy reliably in any given flu season. We're working on this PopVax 🇮🇳.

Behold owl's PopVax poster!

Mike Famulare in response to the questions Eric Gilliam's "What R&D category would you choose to spend many billions per year on?" question: cc Soham Sankaran

The Economist asks: Do viruses trigger Alzheimer’s? I strongly suspect they do! One of our key hypotheses PopVax 🇮🇳 is that latent infection is upstream of lots of nasty long-term illnesses, as demonstrated recently with the linkage of EBV (mono) to multiple sclerosis.

CCAMP was honoured to host Gates Foundation board members including CEO Mark Suzman Helene Gayle @ashishdhawantcf, Minouche Shafik, Tom Tierney, and other executive leadership from Gates Foundation for a visit and interaction with programme and technology leads of select

In this brave new era of global uncertainty, Indians must seize the opportunity to build the technological foundations of an abundant future for all of humanity right here in India. Our best and brightest have often been compelled to leave by needless obstacles and nonexistent

I'm looking for an India-based individual or small team with excellent design sense to design & build a single-page website for a special project PopVax 🇮🇳. We want to start immediately & deploy in a week. If this is you, feel free to reply or DM with links to your work.

PopVax (PopVax 🇮🇳) is honoured to be the subject of Aaryaman Vir's new piece at Tigerfeathers – he's done an excellent job of explaining what we do for a non-biotech audience, as well as outlining the immense opportunity we see in doing cutting-edge biotech R&D in India. More

I'm looking to hire an experienced scientific procurement lead at PopVax 🇮🇳 to manage our sourcing & purchase of research-grade and GMP materials. Expert-level spreadsheet proficiency in Excel or Google Sheets is a non-negotiable qualification, and the ability to write code in

Looking for someone with expertise in yeast tetrad dissection in India for a special project PopVax 🇮🇳 -- if this is you or someone you know, feel free to email me at soham [at] popvax [dot] com.

Thanks to the wonderful Ekta Batra for this short feature about PopVax 🇮🇳 on CNBC-TV18 highlighting our open-source broadly-protective COVID-19 vaccine, our mission to develop vaccines that collectively save 1 million lives per year, and our new cancer immunotherapy work!

Please re-send any emails you sent to PopVax last night or this morning before 8:15am IST.